Rhopressa™ (netarsudil ophthalmic solution) 0.02%
Rocket 4 Phase 3 Topline Results

Important Information

Any discussion of the potential use or expected success of our product candidates is subject to our product candidates being approved by regulatory authorities.

The information in this presentation is current only as of its date and may have changed or may change in the future. We undertake no obligation to update this information in light of new information, future events or otherwise. We are not making any representation or warranty that the information in this presentation is accurate or complete.

Certain statements in this presentation are “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “will,” “should,” “would,” “could,” “believe,” “expects,” “anticipates,” “plans,” “intends,” “estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking statements. These statements are based on the Company’s current plans and expectations. Known and unknown risks, uncertainties and other factors could cause actual results to differ materially from those contemplated by the statements. In evaluating these statements, you should specifically consider various factors that may cause our actual results to differ materially from any forward-looking statements. These risks and uncertainties are described more fully in the quarterly and annual reports that we file with the SEC, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In particular, the topline Rocket 4 data presented herein is preliminary and based solely on information available to us as of the date of this presentation and additional information about the results may be disclosed at any time. In addition, the preclinical research discussed in this presentation is preliminary and the outcome of such preclinical studies may not be predictive of the outcome of later clinical trials. Any future clinical trial results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the preclinical research findings discussed in this presentation. Such forward-looking statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as otherwise required by law.

Rhopressa™ Achieves Primary Clinical Endpoint

- Rhopressa™ QD met the criteria for non-inferiority to timolol BID for the primary efficacy analysis (for baseline IOP < 25 mmHg)
  - Also met non-inferiority for baseline IOP < 27 mmHg and <28 mmHg
- Rhopressa™ QD showed stable efficacy from Week 2 to Month 3
- Consistent efficacy results across multiple statistical analysis imputations (PP/ITT/LOCF)
- The main adverse event for Rhopressa™ was conjunctival hyperemia, which was reported in ~40% of patients and was scored as mild for ~85% of the patients
- There were no drug-related serious adverse events and no evidence of treatment-related systemic effects

Rocket 4 Trial Design

Patients with open angle glaucoma (OAG) or ocular hypertension (OHT)

with IOP > 20 mmHg and < 30 mmHg at 8am,

N = 708 subjects randomized at 52 US sites



Primary endpoints:

- Efficacy: Mean IOP at Weeks 2 and 6 and Month 3 for subjects with baseline IOP > 20 mmHg and <25 mmHg
  (N = 423 subjects per protocol)
- Safety: Ocular and systemic safety during a 6-month treatment period

ClinicalTrials.gov Identifier: NCT02558374

Baseline Demographics

	Rhopressa ™ QD N = 351	Timolol BID N = 357
Gender, n (%)		
Male	143 (40.7%)	120 (33.6%)
Female	208 (59.3%)	237 (66.4%)
Race, n (%)		
White	259 (73.8%)	274 (76.8%)
Black/African American	84 (23.9%)	75 (21.0%)
Asian	7 (2.0%)	6 (1.7%)
Multiple	0 (0%)	1 (0.3%)
Other	1 (0.3%)	1 (0.3%)
Age (years)		
< 65	165(47.0%)	164 (45.9%)
>65	186 (53.0%)	193 (54.1%)
Iris Color, n (%)		
Brown/Black	241 (68.7%)	227 (63.6%)
Blue/Grey/Green	73 (20.8%)	90 (25.2%)
Hazel	36 (10.3%)	40 (11.2%)
Other	1 (0.3%)	0 (0%)

++Data on File
Based on Rocket 4 Topline Interim 3-month

Patient Disposition

	Rhopressa™ QD N = 351	Timolol BID N = 357
Completed Month 3	**290 (82.6%)**	**335 (93.8%)**
Discontinued Prior to Month 3	**61 (17.4%)**	**22 (6.2%)**
Discontinued		
Adverse Event	39 (11.1%)	6 (1.7%)
Withdrawal of Consent	7 (2.0%)	7 (2.0%)
Non-Compliant	1 (0.3%)	1 (0.3%)
Lost to Follow-up	0	0
Lack of Efficacy	5 (1.4%)	0
Disallowed Concurrent Medication	1 (0.3%)	2 (0.6%)
Investigator Decision	0	2 (0.6%)
Protocol Violation	4 (1.1%)	3 (0.8%)
Other	4 (1.1%)	1 (0.3%)

++Data on File
Based on Rocket 4 Topline Interim 3-month

Patient Disposition (For Baseline IOP < 25 mmHg)

	Rhopressa™ QD N = 214	Timolol BID N = 209
Completed Month 3	**189 (88.3%)**	**199 (95.2%)**
Discontinued Prior to Month 3	**25 (11.7%)**	**10 (4.8%)**
Discontinued		
Adverse Event	16 (7.5%)	4 (1.9%)
Withdrawal of Consent	3 (1.4%)	2 (1.0%)
Non-Compliant	1 (0.5%)	1 (0.5%)
Lost to Follow-up	0	0
Lack of Efficacy	1 (0.5%)	0
Disallowed Concurrent Medication	1 (0.5%)	1 (0.5%)
Investigator Decision	0	1 (0.5%)
Protocol Violation	2 (0.9%)	1 (0.5%)
Other	1 (0.5%)	0

++Data on File
Based on Rocket 4 Topline Interim 3-month

Rhopressa™ Achieved Non-Inferiority In the Primary Efficacy Analysis (Baseline IOPs < 25 mmHg)

Mean IOP at Each Time Point (Per Protocol)



++Data on File
Based on Rocket 4 Topline Interim 3-month efficacy

Rhopressa™ Phase 3 Rocket 4, Per Protocol Baseline IOPs < 25 mmHg

	Mean IOP mmHg		Difference from Rhopressa™ QD (95% CI)
	Rhopressa™ QD N=186	Timolol 0.5% BID N=187	
Baseline			
8:00 AM	22.4	22.4	
10:00 AM	21.1	21.3	
4:00 PM	20.7	20.7	
Mean Diurnal	**21.4**	**21.5**	
Day 15			
8:00 AM	17.7	17.5	0.2 (-0.4, 0.8)
10:00 AM	16.6	16.7	-0.2 (-0.7, 0.4)
4:00 PM	16.3	16.9	-0.6 (-1.2, 0.0)
Mean Diurnal	**16.8**	**17.0**	**-0.2 (-0.7, 0.3)**
Day 43			
8:00 AM	17.8	17.6	0.3 (-0.3, 0.9)
10:00 AM	16.8	17.0	-0.2 (-0.8, 0.4)
4:00 PM	16.6	16.7	-0.1 (-0.7, 0.5)
Mean Diurnal	**17.0**	**17.1**	**0.0 (-0.6, 0.5)**
Day 90			
8:00 AM	17.9	17.3	0.6 (0.0, 1.2)
10:00 AM	16.9	16.7	0.2 (-0.4, 0.8)
4:00 PM	16.7	16.8	-0.1 (-0.7, 0.6)
Mean Diurnal	**17.2**	**16.9**	**0.2 (-0.3, 0.8)**

++Data on File
Based on Rocket 4 Topline Interim 3-month efficacy

Summary

- Upper 95% CI ≤ 1.5 mmHg at all time points, ≤ 1.0 mmHg at majority (8/9) time points
  - Rocket 1: ≤ 1.0 mmHg at majority (7/9) time points
  - Rocket 2: ≤ 1.0 mmHg at majority (6/9) time points
- Met the criteria for demonstrating non-inferiority

Rhopressa™ Achieved Non-Inferiority For Baseline IOP < 27 mmHg

Mean IOP at Each Time Point (Per Protocol)



++Data on File
Based on Rocket 4 Topline Interim 3-month efficacy

Rhopressa™ Rocket 4 Efficacy Results for Different Baseline IOPs

Baseline IOP (mmHg)	Non-inferiority
<30	Did not meet**
<28	Met
<27	Met
<26	Met
<25*	Met
<24	Met
<22	insufficient power

*Primary endpoint
** Missed 2 time points by ≤0.03 mmHg

++Data on File
Based on Rocket 4 Topline Interim 3-month efficacy

Rocket 4
Rhopressa™ Synergy with PGAs



Prior PGA



No Prior PGA

- Rhopressa™ synergy with prior PGA use evident at Week 2
- Observed in previous Rhopressa™ trials

++Data on File
Based on Rocket 4 Topline Interim 3-month efficacy

Safety/Tolerability Overview of Rhopressa™

- There were no drug-related serious adverse events (SAEs)
- There was no evidence of treatment-related systemic effects (e.g., clinical laboratory or haematology values, heart rate or blood pressure)
- The most common adverse event was conjunctival hyperemia with ~40% incidence and was scored as mild for ~85% of the patients
- Other ocular AEs
  - AEs occurring in ~5-12% of subjects receiving Rhopressa™ included: conjunctival hemorrhage, cornea verticillata, lacrimation increased and vision blurred

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

Rhopressa™ Phase 3 Safety Profile

Adverse Events (≥5% in any group)	Rhopressa™ QD N = 351	Timolol BID N = 357
Eye Disorders		
Conjunctival Hyperemia	148 (42.2%)	24 (6.7%)
Conjunctival Hemorrhage	41 (11.7%)	7 (2.0%)
Cornea Verticillata	41 (11.7%)	0 (0.0%)
Lacrimation Increased	21 (6.0%)	4 (1.1%)
Vision Blurred	20 (5.7%)	2 (0.6%)
Administration Site Conditions		
Instillation Site Pain	82 (23.4%)	89 (24.9%)
Instillation Site Erythema	36 (10.3%)	3 (0.8%)

Patients with known contraindications or hypersensitivity to timolol were excluded

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

No Change in Mean Hyperemia Score Over Time (Interim Month 3)



- Hyperemia severity did not increase with continued dosing
- Hyperemia was sporadic
  - Only ~16% of patients had hyperemia on each study visit day from week 2 to month 3 (similar to the rates seen for Rocket 1, Rocket 2 and Mercury 1)
  - In Rocket 2, only ~10% of patients had hyperemia on each study visit day from week 2 to month 12

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

When Present, ~85% of Rhopressa™ Hyperemia Graded as Mild



Grade	Image	Description
0		None/Normal
1		Mild
2		Moderate
3		Severe

For illustrative purposes only

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

Rhopressa™ Adverse Events Summary

- Conjunctival Hemorrhage
  - sporadic subconjunctival petechiae

- Cornea Verticillata
  - asymptomatic non-toxic lipid deposits
  - only visible via biomicroscopy evaluation

- Instillation Site Pain
  - same incidence as timolol
  - transient

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

Timolol Caused Statistically Significant Reduction in Heart Rate (Rocket 4)



- Timolol reduced mean heart rate by 2 - 3 beats per minute (average across all patients; $p < 0.001$)
- Despite all measures to exclude patients with possible negative sensitivity to beta-blockers

++Data on File
Based on Rocket 4 Topline Interim 3-month safety

Rhopressa™ Performance Summary To Date

- Well researched with nearly 2,000 clinical patients
- Once-daily efficacy demonstrated in 4 Phase 3 trials (Rocket 1, 2, 4 and Mercury 1)
- Stable efficacy through 12 months
- Synergistic/additive effect with prostaglandin analogues
- Well-tolerated with no evidence of treatment-related systemic effects
- Promising early results: e.g., trabecular meshwork anti-fibrotic/disease modification and 24-hour IOP control

Rhopressa™ and Roclatan™ Key Milestones